Navigation Links
Insulin Pens and Growing Diabetic Community Increase Market for Insulin Delivery Devices in Europe, Says Frost & Sullivan
Date:3/17/2009

LONDON, March 17 /PRNewswire/ -- While insulin syringes are the oldest delivery method available, they are currently experiencing a decline in use in Europe. Several factors have contributed to this trend, the most important being the high acceptance and popularity of insulin pens.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

New analysis from Frost & Sullivan http://www.medicaldevices.frost.com), European Insulin Delivery Devices Market, finds that the market earned revenues of $1,112.8 million in 2007 and estimates this to reach $1,895.0 million in 2014.

If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants with an overview of the European insulin delivery devices market, then send an e-mail to Katja Feick, Corporate Communications, at katja.feick@frost.com, with your full name, company name, title, telephone number, company e-mail address, company website, city, state and country. Upon receipt of the above information, an overview will be sent to you by e-mail.

"The synergies created between pharmaceutical and medical device companies will be a key driver of the insulin pens market in Europe," notes Frost & Sullivan Research Analyst Kieu Vuong. "Another significant factor spurring growth is that insulin pens are more compatible with the fast paced modern environment."

The vast majority of insulin pens are given to patients free when they purchase insulin. This means that suppliers of insulin have a huge impact on the popularity and awareness of related devices. Insulin delivery device manufacturers need to work together with pharmaceutical companies to successfully distribute and promote their products.

The convenience of using insulin pens corresponds well to the needs of today's insulin users. There is a pressing need for a device with high levels of flexibility that requires little commitment in terms of time and effort.

In order to deliver insulin to the subcutaneous tissue, a needle injection is the most straightforward method. Needle phobia is however a significant deterrent for patients.

"Needle phobia has always represented the biggest restraint to the growth of the insulin syringes market," explains Vuong. "Needle phobia is not only an issue among new users and children but also among adult insulin users."

Perhaps the most effective method to achieve adequate dissemination of insulin for diabetic patients is through promoting the cooperation of insulin suppliers (pharmaceutical companies) and insulin delivery device manufacturers. Currently, only a few big multinational firms manufacture their own devices.

"Accordingly, one of the biggest and most important challenges for manufacturers of emerging insulin delivery devices is to build a close business relationship with pharmaceutical companies," advises Vuong. "Insulin pens are a good example of this kind of cooperation."

Through cooperative agreements and projects, both companies can benefit from mutual synergies and save on additional capital investments and operation costs, even while extending their product portfolio.

European Insulin Delivery Devices Market is part of the Medical Devices Growth Partnership Service programme, which also includes research in the following markets: European Bone Growth and Spinal Fusion Stimulators Markets, European Patient Temperature Management Market, European Device Disinfection and Sterilisation Equipment Market and European Markets for Haemostats and Tissue Sealants. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.

Frost & Sullivan has expanded its flagship Global Congress on Corporate Growth - GIL Global - into several major cities around the world including London. For the first time ever in Europe, Frost & Sullivan will be hosting the Growth, Innovation and Leadership Congress 'GIL 2009: Europe' on 19-20 May, at the Sofitel St James in London. GIL Global is the industry's only event designed to support senior executives in their efforts to achieve sustainable, top-line growth. To register, obtain a programme agenda, explore sponsorship opportunities, or attend as a member of the media for GIL 2009: Europe, please contact Katja Feick, Corporate Communications Europe, at katja.feick@frost.com. One-on-One interviews with Frost & Sullivan senior growth consultants are also being scheduled. For more information you can also visit http://www.frost.com/gilglobal

Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership(TM) empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan's Growth Partnership Services, visit http://www.frost.com.

European Insulin Delivery Devices Market

M2CD

    Contact:
    Katja Feick
    Corporate Communications - Europe
    P: +49 (0) 69 77033 43
    E: katja.feick@frost.com
   http://www.frost.com/


'/>"/>
SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Fat on chest and upper back increases risk of insulin resistance
2. Scientists explain how insulin secreting cells maintain their glucose sensitivity
3. Smart insulin nanostructures pass feasibility test, UT study reports
4. FDA Clears MDN-CGS(R) Intravenous Insulin Dosing Software
5. Mayo Clinic researchers: Insulin-boosting medication does not impair ability to survive heart attack
6. Landmark trial to evaluate cardioprotective properties of insulin
7. Medtronic Mediterranean Launches Worlds First Arabic-Language Integrated Insulin Therapy for Improved Diabetes Management
8. BCP Veterinary Pharmacy Helps Cure Diabetic Cats with BCP PZI(R), the Closest Match to Feline Insulin Available
9. Living donors may be best source of insulin-producing islets for diabetes treatment
10. Insulin regulates the secretion of the antiaging hormome Klotho
11. Protein power: Researchers trigger insulin production in diabetic mice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 2016 One of Australia,s successful ... of a new biotechnology company, Noxopharm Limited [ABN 50 608 966 ... and to list on the ASX. Noxopharm is a ... enter a Phase 1 clinical study later this year. ... of the biggest problems facing cancer patients - the ability of ...
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/26/2016)... -- VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported today ... to build a strong and stable market for trading ... the OTC Markets-pink current trading platform. Explains ... seeing an anomaly in market trading activities that may ... Company, but shareholders and market players as well. I ...
Breaking Medicine Technology: